Compare First Citizens BancShares Inc (FCNCA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Twist Bioscience Corp — how do they compare? First Citizens BancShares Inc trades at $2,163.07 (market cap $23.76B), while Twist Bioscience Corp trades at $89.52 (market cap $5.76B). The key difference: First Citizens BancShares Inc is far larger — about 4.1× Twist Bioscience Corp's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| FCNCA | TWST | |
|---|---|---|
Market Cap | $23.76B | $5.76B |
Sector | Sector/Thematic | Health |
52-Week High | $2.20K | $102.88 |
52-Week Low | $1.64K | $24.16 |
Dividend Yield | 0.41% | — |
Enterprise Value | — | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,133.72, up 3.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a trailing P/E of 11.94 and consistent earnings beats, including a Q1 2026 EPS of $44.86 versus $39.56 expected. Recent strategic moves include plans to retire the Silicon Valley Bank brand and expand commercial banking capabilities in Q4 2026.
The outlook is supported by solid profitability with a 24.35% net income margin and a shareholder-friendly dividend. Key risks include margin pressure and credit risk exposure from the legacy SVB portfolio. Analyst consensus is cautious with an 81.82% hold rating, though the consensus price target of $2,320 suggests modest upside from current levels.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
